Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer | Synapse
July 21, 2004Open Access
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Key Points
This research aims to assess the effectiveness of cetuximab alone and in combination with irinotecan for treating irinotecan-refractory metastatic colorectal cancer.
Evaluated cetuximab monotherapy and combination with irinotecan in a clinical setting.
Focused on patients with irinotecan-refractory metastatic colorectal cancer.
Cetuximab showed significant clinical activity as monotherapy.
Combination therapy with irinotecan resulted in enhanced effectiveness compared to monotherapy.
Abstract
Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer.